As the pipeline of novel vaccines expands, so does the pipeline for other “vaccine-like” products.
Although influenza disease burden is high, vaccine uptake remains low.
Nearly 80,000 people died during the 2017–2018 influenza season. Only 37% of adults were vaccinated. Several novel emerging products could make vaccination more accessible and effective, potentially reshaping the market and lowering influenza disease burden.